Description

Appropriate selection of biochemical targets is one of the most important drivers of cost effectiveness in the discovery of new medicines. Despite the many advances in genetics, genomics and systems biology, ‘validation’ of a target is not achieved until therapeutic efficacy is demonstrated by a drug candidate. Volume 46 of this series reviews the medicinal chemistry aimed at six diverse targets from which important new medicines are emerging: * HIV integrase (discovery of the first-in-class inhibitor drug raltegravir) * 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation) * Nicotinic a7 choline receptor (agonists and positive allosteric modulators). * Bradykinin receptor (new approach to pain therapy) * Histone deacetylase (new drugs for cancer) * 5-HT2c receptor modulators (various CNS indications)

Key Features

*Presents the latest research in the field of drug discovery *Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

Readership

Chemists, biologists, doctors, pharmacists and anyone interested in the contemporary controversy about drugs, drug firms, and the community

Table of Contents

* HIV integrase (discovery of the first-in-class inhibitor drug raltegravir) * 11-beta-Hydroxysteroid dehydrogenase (new approach to glucocorticoid regulation) * Nicotinic a7 choline receptor (agonists and positive allosteric modulators) * Bradykinin receptor (new approach to pain therapy) * Histone deacetylase (new drugs for cancer) * 5-HT2c receptor modulators (various CNS indications)

Details

No. of pages:
420
Language:
English
Copyright:
© 2008
Published:
Imprint:
Elsevier Science
eBook ISBN:
9780080569680
Print ISBN:
9780444530189
Print ISBN:
9780444559760